A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2018
At a glance
- Drugs MEDI-2228 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms MEDI2228
- Sponsors MedImmune
- 23 May 2018 Planned End Date changed from 10 Aug 2020 to 23 Apr 2021.
- 23 May 2018 Planned primary completion date changed from 10 Aug 2020 to 23 Apr 2021.
- 23 May 2018 Status changed from not yet recruiting to recruiting.